FDA grants accelerated approval to new treatment for advanced ovarian cancer

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: FDA grants accelerated approval to new treatment for advanced ovarian cancer

View as a webpage

News Release

For Immediate Release:

December 19, 2016

Media Inquiries:

Angela Stark, 301-796-0397, angela.stark@xxxxxxxxxxx �

Consumer Inquiries:

888-INFO-FDA

FDA grants accelerated approval to new treatment for advanced ovarian cancer

The U.S. Food and Drug Administration today granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. Rubraca is approved for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as identified by an FDA-approved companion diagnostic test.

Read more.

###

---

Subscriber Services:
Manage Preferences��|��Unsubscribe��|��Help with this service

Stay Connected:

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) � 10903 New Hampshire Ave � Silver Spring, MD 20993 � 1-888-INFO-FDA (1-888-463-6332)